Big pharma, Partnering

Bayer and geneData in workflow management system pact

Posted on 18 March 2015

Tags: , ,

Genedata announced a collaboration with Bayer Pharma to develop a new workflow management system to support the automation of the Cell Line Development (CLD) process for mammalian cells used to produce biopharmaceuticals.

Genedata's new CLD Data Platform is an enterprise software system that boosts the efficiency of cell line and process development and increases process quality.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

It tracks all clones produced and screened in high-throughput mode, collects all relevant characterization data, such as productivity and quality parameters, and streamlines high-throughput workflows by interfacing with automation equipment such as pipetting robots, measurement devices, and bioreactors.

The CLD Data Platform enables a seamless and smooth generation of GMP-ready cell lines and their transfer into process development.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply